HLA‐B*5801: utility and cost‐effectiveness in the Asia‐Pacific Region
Author:
- 26 April 2013
- journal article
- review article
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 16 (3) , 254-257
Abstract
Gout is a common condition which is mainly treated with the hypo‐uricemic agent, allopurinol. Although allopurinol is generally a well‐tolerated drug, there is a small risk of developing potentially fatal complications, such as allopurinol hypersensitivity syndrome. Recent advances in pharmacogenomics have made possible the identification of genes which confer susceptibility to specific drugs. A recent multi‐national case‐control study has reported allopurinol as the most common drug associated with Stevens‐Johnson syndrome and toxic epidermal necrolysis. Several studies have established a strong association between the human leukocyte antigen (HLA)‐B*5801 gene and development of Stevens‐Johnson syndrome and toxic epidermal necrolysis. The allele frequency of HLA‐B*5801 is highest in the South East Asian population.Since other hypo‐uricemic agents are available, patients may wish to have HLA‐B*5801 testing before being started on allopurinol. As the test for HLA‐B*5801 is expensive, time‐consuming and only available in selected laboratories, there is a need to evaluate the utility and cost‐effectiveness of this test in our region.Keywords
This publication has 21 references indexed in Scilit:
- Association of HLA-B*5801 allele and allopurinol-induced stevens johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysisBMC Medical Genetics, 2011
- Initiating allopurinol therapy: do we need to know the patient's human leucocyte antigen status?Internal Medicine Journal, 2011
- Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in KoreansPharmacogenetics and Genomics, 2011
- Drug hypersensitivity: Pharmacogenetics and clinical syndromesJournal of Allergy and Clinical Immunology, 2011
- PSS14 WHAT COST OF HLA-B*5801 GENOTYPING WOULD BE COST EFECTIVE FOR THE PREVENTION OF ALLOPURINOL-INDUCED STEVENS JOHNSON SYNDROME/TOXIC EPIDERMAL NECROLYSIS IN THAILAND: ANALYSES USING A DECISION-ANALYTIC MODELValue in Health, 2010
- Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai populationPharmacogenetics and Genomics, 2009
- Rheumatic Diseases in ChinaArthritis Research & Therapy, 2008
- Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Assessment of Medication Risks with Emphasis on Recently Marketed Drugs. The EuroSCAR-StudyJournal of Investigative Dermatology, 2008
- Acute adverse reactions attributed to allopurinol in hospitalised patients.Annals of the Rheumatic Diseases, 1981
- Severe Hypersensitivity Reactions to AllopurinolSouthern Medical Journal, 1979